TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02316171
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03321188
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant IV chemotherapy
Study: NCT03321188
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant IV chemotherapy
Study: NCT04622202
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral capsule pregabalin 150 mg.
Study: NCT04622202
Drug: multivitamin
Normalized name: multivitamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral placebo in the form of oral multivitamin capsule.
Study: NCT02636803
Drug: oxfendazole
Normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
Study: NCT02636803
Drug: albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group receives one 400 mg dose of albendazole
Study: NCT01505179
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
Study: NCT00350779
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
Study: NCT00543634
Drug: Provera 10 mg
Normalized name: Provera 10 MG Oral Tablet
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of MPA, 4 tablets dissoved in water
Study: NCT00350779
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study: NCT00350779
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study: NCT00350779
Drug: glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
Study: NCT02326740
Drug: gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02326740
Drug: gevokizumab open-label
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01369147
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
Study: NCT01369147
Drug: Clevidipine
Normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
Study: NCT01369147
Drug: Dextrose-containing IV Fluids
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
Study: NCT03185845
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tailored dose according to international normalized ratio (INR) for 3 months
Study: NCT00119756
Drug: paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03964038
Drug: gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT03964038
Drug: gilteritinib mini tablet
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT03255915
Drug: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
Normalized name: emtricitabine / tenofovir disoproxil fumarate Pill
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
Study: NCT00911183
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00911183
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02242370
Drug: Low dose of telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02242370
Drug: High dose of telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02540967
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadovist dosage following summary of product characteristics
Study: NCT01096680
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 250 mg
Study: NCT00183235
Drug: aripiprazole (up to 15 mg/day) for 8 days
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00203502
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV 15mg/kg 21 days
Study: NCT00203502
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg per meter squared, IV every 21 days
Study: NCT03963375
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
Study: NCT00005908
Drug: Docetaxel - Dose A
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
Study: NCT00005908
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg orally daily for five years
Study: NCT00005908
Drug: Docetaxel - Dose B
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
Study: NCT00005908
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day orally for five years
Study: NCT01372202
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
Study: NCT01372202
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29.
Study: NCT01372202
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 days 1, 15, 29.
Study: NCT03486964
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
Study: NCT03704506
Drug: amoxil capsule
Normalized name: Amoxi Drop
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
Study: NCT03532776
Drug: Podofilox Gel 0.5%
DrugBank: Podofilox (DB01179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Study: NCT01385956
Drug: SOM 230 LAR
Normalized name: Wal-Som
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
Study: NCT01385956
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
Study: NCT01134861
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
Study: NCT01134861
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
Study: NCT01134861
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/m2 i.v. bolus weekly first 5 weeks of RT
Study: NCT01134861
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
Study: NCT01372202
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29.
Study: NCT00003359
Drug: batabulin sodium
Normalized name: Batabulin
DrugBank: Batabulin (DB16103)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03556345
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/kg IV every 2 weeks
Study: NCT03029845
Drug: Propranolol 1
Normalized name: propranolol 120 MG
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 20 mg propranolol twice a day for 2 weeks
Study: NCT03029845
Drug: Propranolol 2
Normalized name: propranolol 20 MG
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 10 mg propranolol twice a day for 2 weeks
Study: NCT01306409
Drug: ESA
Normalized name: GenESA
DrugBank: Arbutamine (DB01102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential application of three different ESA
Study: NCT00511654
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
Study: NCT03411902
Drug: Risedronate Sodium 150 MG
Normalized name: risedronate sodium 150 MG
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
Study: NCT00595101
Drug: PF-03187207
Normalized name: PF-03187207
DrugBank: PF-03187207 (DB05746)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00595101
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02970721
Drug: Antipsychotic and Antidepressant
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Polytherapy
Study: NCT00595101
Drug: PF-03187207 Vehicle
Normalized name: PF-03187207
DrugBank: PF-03187207 (DB05746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
Study: NCT00595101
Drug: Latanoprost Vehicle
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02429037
Drug: rAd-p53
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
Study: NCT02429037
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
Study: NCT01980745
Drug: Chloroquine diphosphate 250mg
Normalized name: chloroquine diphosphate, (R)-
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
Study: NCT01611428
Drug: Ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral and Intravenous (i.v.)
Study: NCT01776840
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
Study: NCT01776840
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
Study: NCT01776840
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
Study: NCT02042170
Drug: human growth hormone self-injection
Normalized name: Growth hormone (human)
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01171885
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of Ropivacaine 0.25%.
Study: NCT01171885
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of Ropivacaine 0.5%.
Study: NCT03052478
Drug: Vismodegib 150 mg
Normalized name: vismodegib 150 MG
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
Study: NCT04492787
Drug: Changkang Granule
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Changkang granule before meals twice a day , one bag for each time
Study: NCT00607789
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/day - 120 mg/day
Study: NCT00582985
Drug: TRC105 chimeric anti-CD105 antibody
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
Study: NCT04518345
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04518345
Drug: Dubermatinib
Normalized name: Dubermatinib
DrugBank: Dubermatinib (DB15187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03120949
Drug: Olokizumab 64 mg SC q4w
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Study: NCT03120949
Drug: Olokizumab 64 mg SC q2w
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Study: NCT05789667
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated by lenvatinib as recommended by good clinical practice
Study: NCT01247922
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous oral Erlotinib 85 mg/m\^2 per day
Study: NCT00515281
Drug: oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
Study: NCT01662661
Drug: JNJ-47910382 (suspension)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
Study: NCT01662661
Drug: JNJ-47910382 (tablet)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
Study: NCT03627130
Drug: Potassium Nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
Study: NCT03627130
Drug: Potassium Chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium Chloride capsules for 5 days
Study: NCT02950870
Drug: Ombitasvir-Paritaprevir-Ritonavir
Normalized name: ombitasvir / paritaprevir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
Study: NCT02950870
Drug: Dasabuvir
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient will be treated daily with Dasubavir 500 mg total dose
Study: NCT02950870
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with ribavirin if necessary.
Study: NCT04333225
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly treatment in individuals at high risk
Study: NCT01703559
Drug: Phentolamine Mesylate Ophthalmic Solution 0.5%
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study: NCT02971683
Drug: Abatacept subcutaneous
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose of Abatacept subcutaneous on specified days
Study: NCT01922154
Drug: intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
Study: NCT00621517
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partipants will receive 150 mg bupropion per night
Study: NCT00739024
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet, oral, once daily
Study: NCT03289299
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
Study: NCT03289299
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase.